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Liposomal encapsulation of the individual light and heavy chain of botulinum neurotoxin A was used to investigate their intra-cellular effects on 
synaptic transmission at the murine neuromuscular junction. Bath-application to phrenic nerve-hemidiaphragms of liposomes containing heavy 
chain (up to 75 nM) caused no alteration in neurally-evoked muscle tension. In contrast, liposomes with entrapped light chain (9-20 nM final 
concentration) gave a pre-synaptic blockade of neuromuscular t ansmission that could be relieved temporarily by 4-aminopyridine, as for the di- 
chain toxin. Any contribution from contaminating intact toxin was excluded both by the purity and minimal toxicity in mice of the light chain 
preparations used, and by the lack of neuromuscuiar paralysis seen with liposomes containing the maximum amount of native toxin that could 
have been present in the light chain liposomes. As bath-application of high concentrations of light chain in the absence of liposomes failed to 
affect neurotransmiter release, it is concluded that this chain alone can mimic the action of the whole toxin inside mammalian motor nerve endings, 
its predominant site of action. Thus, light chain could provide a more effective probe for an intra-cellular component concerned with Ca2”-depend- 
ent secretion. 
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1. INTRODUCTION 
Botulinum neurotoxin A (BoNT), one of a family 
(types A-G) of high molecular weight proteins (M 
= 150 ~) produced by strains of C~~stri~~u~ 
botulinurn (reviewed in [ 1 J), preferentially and irrever- 
sibly inhibits the release of acetylcholine (ACh) in the 
peripheral nervous system [2], The active di-chain form 
of the toxin consists of a heavy chain (HC; 
M, z 100 000) and a light chain (LC; h&z 50 000) join- 
ed by at least one disulphide bond [I]. Intoxication ap- 
pears to involve a tri-phasic pathway [2]: (i) toxin bin- 
ding to a specific ecto-acceptor on the pre-synaptic 
membrane - an innocuous process; (ii) an internalisa- 
tion step with a relatively high Qia; and (iii) an intra- 
cellular event that inhibits neurotransmitter elease. 
Although this model has been documented by ex- 
perimentation in various ceI1 systems [3-71 an intra- 
neuronal action of BoNT or its chains has not yet been 
demonstrated at motor endplates. 
the C-terminal (HI) half of the HC abolishes its 
neuroparalytic activity in vitro [8]. Likewise, the 
renatured, individual chains of BoNT are ineffective in 
blocking neuromuscular transmission, and a mixture of 
WC and LC inhibits with relatively low potency 191. 
However, in Ap/ysia cajifornica the HC (or the N- 
terminal moiety (Hz)) can mediate acceptor-dependent 
translocation of LC [4,8] indicating a less stringent 
structural requirement for toxin uptake. When applied 
intra-cellularly to chromaffin cells [5,6] or added to 
permeabilised PC-12 cells [7], LC alone does inhibit 
Ca2 + -evoked noradrenaline release. In contrast, in 
Aplysia, inhibition of quanta1 release of neurotransmit- 
ter by intra-neuronally administered LC does not occur 
until HC is micro-injected inside or added to the bath 
[4]. A further anomaly is that the LC of tetanus toxin, 
a related C~osfr~~iai protein, blocks neurotransmitter 
release when injected in Aplysia [lo]. 
For optimal activity of BoNT at the neuromuscular 
junction the di-chain molecule is required; removal of 
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Hence, it is important to establish if LC of BoNT is 
active inside mammalian motor nerve terminals, its 
prime target. As the permeabilisation techniques used 
for cultured cells [S-7] are not applicable to this 
preparation, in the present study BoNT or its chains 
were delivered via liposomes and their effects on ACh 
release were assessed by measuring changes in nerve- 
evoked muscle tension. 
Abbreviafio~: BoNT, botulinum neurotoxin A; LC and HC, light 
and heavy chain; ACh, acetylcholine; PC, phosphatidyl choline; PS, 
phosphatidyl serine; Hepes, N-(2-hydroxyethyl)piperazine-N- 
(2-ethanesulphonic acid); 4-AP, 4-aminopyridine; SDS-PAGE, 
sodium dodecyl sulphate-polyacrylamide g l electrophoresis 
2. EXPERIMENTAL 
2. I. Materials 
Egg phosphatidyl choline (PC) and phosphatidyl serine (PS) were 
obtained from Lipid Products (South Nutfield, Surrey), cholesterol 
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from Sigma Chem. Co. (Poole, Dorset); Sephacryl S200 HR from 
Pharmacia Ltd. (Milton Keynes, Bucks.). 
2.2. Preparation of LC and HC 
BoNT was purified to homogeneity as detailed previously (111. For 
preparations containing significant proportions of the single-chain 
species, the di-chain form was created by limited proteolysis in 50 mM 
triethanolamine/HCl buffer, pH 7.7, with Arg C (20 units/mg pro- 
tein) at 37°C for 60 min. After arresting the digestion with tosyl-l- 
lysine chloromethyl ketone (2 mM), LC and HC were isolated 
chromatographically using an established procedure [Q]. The purity of 
the chains was ascertained by sodium dodecyl sulphate- 
polyacrylamide gel electrophoresis (SDS-PAGE) and mouse toxicity. 
As the toxicity of the constituent chains is many orders of magnitude 
lower than the native toxin (= lo8 LD&mg), the mouse bioassay pro- 
vided a sensitive method of determining any contamination by the 
native toxin, that would be undetectable by silver staining of SDS- 
PAGE gels. LC and HC were renatured by dialysis into 118 mM 
NaCI/IO mM Hepes, pH 7.4, over 5 h (with 3 changes of buffer) at 
4°C before preparing liposomes. 
2.3. ‘Z’I-Labelling of BoNT, LC and HC 
BoNT type A was radioiodinated to a high specific activity (= 500 
Ci/mmol) as described elsewhere [12] and the iodinated chains 
separated using the protocol referred to above and gave specific ac- 
tivities of = 100 Ci/mmol and ~400 Ci/mmol, respectively. 
2.4. Liposome preparation 
Liposomes were prepared using a modification of a previously 
described method [13]. Chloroform solutions of PC/cholesterol/PS 
in a 7:2:1 ratio (w/w) were mixed and dried under vacuum. The lipids 
were suspended in 4 ml of I IS mM NaCl/lO mM Hepes, pH 7.4, con- 
taining LC, HC or BoNT (0.25 mmol lipidlpmol protein; the approx- 
imate M, of PS and PC was taken as 850). Because of the need to use 
minute amounts of BoNT (see below), heat-inactivated bovine serum 
albumin was added to the lipid suspension to adjust the total protein 
content to that of the LC or HC used in the preparation of liposomes. 
Trace amounts of the respective iodinated chains or BoNT were in- 
cluded to allow quantitation of their subsequent entrapment by 
liposomes. The lipid/protein mixtures were vortexed repeatedly over 
30 min at 4°C before sonicating for I min with a MSE probe 
sonicator. After standing for 30 min at 4”C, the mixtures were loaded 
onto a Sephacryl S200 HR column (2.5 x 20 cm) previously 
equilibrated in the NaCl/Hepes buffer at 4°C. The liposome peak 
(6-8 ml) was detected by measuring turbidity (&canm) of the fractions 
collected and the protein quantified by counting radioactivity. The 
pooled Iiposome peak was dialysed over 14-16 h at 4°C into Krebs 
solution of the following composition (mM): Na’ 143.0, K+ 5.9, 
Mg*+ , , 1 2 Ca*’ 2.5, Cl- 127.7, HCO,- 25.0, HzP04- 1.2, SOS’- 
1.2, glucose 11.1, pH 7.4. Samples were aerated (95% 02/5% CGz) 
before applying to the nerve-diaphragm preparations. 
2.5. Measurement of neuromuscular transmission 
Left phrenic nerve hemidiaphragms were dissected from Balb/C 
mice (20-25 g) and transferred immediately to a closed circulating 
superfusion system containing 15 ml of aerated (95% 02/5% CO2) 
Krebs solution maintained at 37°C. Muscle twitch was evoked by 
stimulating the phrenic nerve supra-maximally (0.2 Hz square waves 
of 0.1 ms duration and 1.5 V amplitude); muscle tension was 
measured using a force/displacement ransducer attached to a 
polygraph 19). Paralysis time was defined as that taken to give a 90% 
reduction of the initial nerve-evoked muscle tension 1141. 
3. RESULTS 
The liposomes prepared in this study were required to 
encapsulate BoNT or its chains, and to be capable of 
fusing with the pre-synaptic membrane. To minimize 
the complication of toxin chains associating with the 
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lipids rather than being entrapped inside vesicles, 
negatively-charged lipids were used for liposome 
preparation; this excludes electrostatic interaction of 
toxin or its chains (BoNT ~1~6.3) [ll) with the 
liposomal lipids. However, the HC of BoNT is known 
to interact hydrophobically with liposomes at neutral 
pH [ 161. Accordingly, when HC or BoNT was mixed 
with the lipids after sonication and the mixtures 
separated chromatographi~ally (Fig, IA,C) each 
associated with the liposomes, though to a limited ex- 
tent (~5% of the total protein). Consistent with the 
lower hydrophobicity of the LC, its addition to 
. 
1 2 
. ._ 
0;’ 
IO 
-1 
x 
E 
0” 
-0 
2 
. 
i . 
5 uy 
00’ 
m- 
; 
a 
V 
-C 
15 25 35 4515 25 35 
FRACTION NO. 
i 
: 
Fig. 1. Gel filtration of BoNT and its chains encapsulated in or 
associated with liposomes. Liposomes were prepared as described in 
section 2.4. The proteins together with radioiodinated 
tracer/liposome mixtures were loaded onto a Sephacryl S200 HR col- 
umn and eluted at a flow rate of 1 ml/min and 1.5 ml fractions col- 
lected. The liposome and protein peaks were detected by determining 
the absorbance at 600 nm and radioactivity of each fraction. (A,C,E) 
Elution of preformed liposomes that were incubated for 30 min at 
4°C with HC (A), BoNT (C) or LC (E) prior to application to the col- 
umn. (B,D,F) Elution of liposomes containing HC (B), BoNT (D) or 
LC (F) prepared by sonication of the lipids in the presence of BoNT 
or its chains. 
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previously sonicated lipids resulted in negligible 
association with the liposome peak (Fig. 1E). At 37”C, 
the liposomes were fluid and did deliver their contents 
into both nerve and muscle; this was established by 
measurement of uptake of an inert radioactive tracer in- 
to endplate-enriched and non-endplate-containing 
areas of diaphragm (data not shown). Importantly such 
fusion of liposomes, devoid of toxin but containing the 
buffer used in the twitch experiments, failed to alter 
nerve-evoked muscle tension of diaphragm prepara- 
tions (Fig. 2). 
The level of encapsulation of HC into liposomes (Fig. 
1B) was 70-80% of the total HC added (~375 nM). 
When these liposomes were bath-applied to the medium 
superfusing the diaphragm, at a final concentration up 
to ~75 nM, no detectable change in twitch tension 
resulted (Fig. 2); this is in accordance with the low tox- 
icity of the HC preparations in mice (= lo3 LDso/mg; 
= 105-fold less toxic than BoNT). In the case of the LC, 
5-10% of that added (= 750 nM) to the lipid suspension 
became incorporated into liposomes (Fig. IF). Notably, 
this liposome-entrapped LC decreased nerve-evoked 
muscle twitch tension (Fig. 2). In two separate ex- 
periments, = 15 and ~20 nM encapsulated LC (final 
concentration in the bath) gave 90% paralysis after 
= 110 min with a lag time of = 40 min. A third liposome 
preparation containing a lower concentration of LC 
” L 4 
Time (hrs.) 
Fig. 2. Effect of control liposomes and those containing BoNT, HC 
or LC on neuromuscular t ansmission. Liposomes were dialysed into 
aerated Krebs solution and bath applied to mouse phrenic nerve- 
hemidiaphragm preparations which were superfused at 37°C and 
stimulated supra-maximally. Nerve-evoked muscle tension, expressed 
as a % of the initial value was measured against time. Control 
liposomes, lacking protein (0) failed to produce any change, as did 
liposomes entrapping HC (0) at a final concentration in the bath of up 
to ~75 nM. Liposomes encapsulating LC at final concentrations of 
-20 nM (+), 45nM(r)and = 9 nM ( n ) decrease muscle tension. 
A fourth preparation of liposome-entrapped LC also gave the ex- 
pected intoxication (data not shown). Liposome-entrapped BoNT at 
a final bath concentration of -0.2 pM (0). representing the 
maximum amount of contaminating BoNT that could have been pre- 
sent in the LC liposomes (see section 3), produced no change. The 
results shown for the control, HC and BoNT liposomes were each 
repeated twice; the data presented for the LC liposomes were obtained 
with different chain preparations. 
( = 9 nM in the bath) elicited a decrease in nerve-evoked 
muscle tension with longer lag (= 140 min) and 
paralysis (5 280 min) times. Variation in the prepara- 
tion of liposomes and the consequential differences in 
the extent of fusion probably underlies the dispropor- 
tionate lower potency of the latter sample. It appears 
that a pre-synaptic blockade occurred because addition 
to the bath of 4-aminopyridine (4-AP; 0.2 mM) after 
paralysis by the LC liposomes caused a near-complete, 
though temporary, recovery of muscle-tension. 4-AP 
increases neuronal activity by increasing Ca2+ influx 
due to blockade of voltage-activated K + channels [ 15 1. 
Furthermore, the neuroparalysis observed seems to 
be attributable solely to LC because no contaminants 
were revealed by SDS-PAGE and silver staining of the 
preparations used. Also, mouse bioassay indicated tox- 
icities for LC of 103-lo4 LD&mg (at least 104-fold less 
toxic than the native toxin). To exclude the possibility 
that the toxicity seen with LC was due to any con- 
taminating native toxin being encapsulated with the 
L,C, liposomes were prepared with the maximum 
amount of BoNT that could have been present in the 
LC samples (calculated from the mouse toxicity values 
as O.Ol%, assuming LC alone is non-toxic). The incor- 
poration of 0.8 pM BoNT (Fig. 1D) into liposomes was 
again, like the HC, much higher (94-98%) than that of 
LC. No change in muscle tension was observed after ad- 
dition of these liposomes (= 0.2 pM BoNT in the bath) 
to the nerve-diaphragm preparation (Fig. 2). Therefore, 
this study has shown that the LC, without the HC, once 
delivered intracellularly does inhibit ACh release from 
mammalian motor nerves. 
4. DISCUSSION 
The ability of liposomes to transport drugs and 
macromolecules across membrane barriers [ 171 has 
been utilized herein to deliver the HC or LC of BoNT 
into the cytoplasm of motor nerve terminals. By- 
passing binding and internalisation in this manner 
allowed an assessment o be made of the chains’ 
abilities to inhibit ACh release. The observed toxicity of 
liposomes containing LC establishes, for the first time, 
that it alone is capable of blocking synaptic transmis- 
sion at mammalian nerve-muscle ndplates, any con- 
tribution from contaminating native toxin having been 
eliminated. Also, these results reaffirm that the LC acts 
intra-cellularly because bath-application to the tissue of 
high concentrations (30 nM) of LC in the absence of 
liposomes failed to affect ACh release [9]. These fin- 
dings accord with observations made on chromaffin 
[5,6,18] and PC-12 cells [7] using LC of BoNT or 
tetanus toxin. Moreover, the nature of the LC-induced 
pre-synaptic blockade resembles that of BoNT [15] 
because the neuroparalytic effects of both can be 
reversed temporarily by 4-AP. It is not readily possible 
to determine the absolute potency of liposome- 
173 
Volume 277, number 1,2 FEBSLETTERS December 1990 
delivered LC due to the disproportionately large surface 
area of non-neuronal membrane compared to the 
minute amount of that from the pre-synaptic nerve ter- 
minal with which the liposomes could fuse. 
Curiously, both chains of BoNT are required intra- 
cellularly for the inhibition of quanta1 release of ACh 
from Apfysia neurons [4]. This is suggestive of a secon- 
dary role for HC, particularly because LC alone of 
tetanus toxin is active in the same invertebrate neurons 
[lo]. The success reported here in delivering LC into 
motor nerve endings could lead to a novel treatment for 
botulism. This would entail using non-toxic derivatives 
of BoNT to target liposomes with entrapped neutralis- 
ing antibodies via interaction with ecto-acceptors uni- 
que to cholinergic nerve membranes [3]. 
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